...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.
【24h】

Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.

机译:特异于髓鞘碱性蛋白的人T细胞克隆中环状核苷酸磷酸二酯酶3和4活性的差异表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Little is known concerning the relative distribution and function of the different cyclic nucleotide phosphodiesterases (PDEs) in lymphocytes. Recent reports, however, have indicated that specific PDE4 inhibitors were effective in treatment of experimental allergic encephalomyelitis, an animal model of multiple sclerosis. The therapeutic effect of PDE4 inhibitors is thought to be related to inhibition of autoreactive CD4+ T cells specific for myelin basic protein (MBP) or other myelin proteins. Human autoreactive CD4+ T lymphocyte clones (TCC), specific for the immunodominant MBP epitope (amino acids 83-99), contain PDE3 and PDE4, two PDEs that exhibit a high affinity for cAMP. Amplification of TCC mRNA by reverse transcription-PCR indicated that TCC PDE3 mRNA was of the PDE3B, not PDE3A, subtype. Different TCC contained different proportions of PDE3 and PDE4, and their activities increased during Ag (MBP) stimulation. Specific PDE3 (cilostamide) and PDE4 (rolipram) inhibitors suppressed [3H]thymidine incorporation in TCC. Since it is believed that many autoimmune diseases are at least partially mediated by autoreactive CD4+ T cells, these observations may have important implications not only for the treatment of multiple sclerosis but also for other autoimmune diseases.
机译:关于淋巴细胞中不同环核苷酸磷酸二酯酶(PDE)的相​​对分布和功能的了解甚少。但是,最近的报道表明,特定的PDE4抑制剂可有效治疗实验性变应性脑脊髓炎(一种多发性硬化症的动物模型)。人们认为PDE4抑制剂的治疗作用与抑制对髓磷脂碱性蛋白(MBP)或其他髓磷脂蛋白具有特异性的自身反应性CD4 + T细胞有关。特异于免疫优势MBP表位(氨基酸83-99)的人自身反应性CD4 + T淋巴细胞克隆(TCC)含有PDE3和PDE4,这两个PDE对cAMP表现出高亲和力。通过逆转录-PCR扩增TCC mRNA表明TCC PDE3 mRNA是PDE3B的亚型而不是PDE3A的亚型。不同的TCC含有不同比例的PDE3和PDE4,它们的活性在Ag(MBP)刺激过程中增加。特定的PDE3(西洛酰胺)和PDE4(咯利普兰)抑制剂可抑制[3H]胸苷掺入TCC。由于据信许多自身免疫性疾病至少部分地由自身反应性CD4 + T细胞介导,因此这些观察结果可能不仅对多发性硬化症的治疗具有重要意义,而且对其他自身免疫性疾病也具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号